VRTX NASDAQ
Vertex Pharmaceuticals Incorporated
1W: +1.2%
1M: -1.3%
3M: +7.8%
YTD: +15.2%
1Y: +23.6%
3Y: +44.0%
5Y: +181.0%
$521.03
+3.54 (+0.68%)
Pre-Market: $528.45 (+7.42, +1.42%)
Weekly Expected Move ±4.1%
$480
$502
$524
$546
$567
Credit Risk of going bust: lower than 94% of companies Debt: 1.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.52 (down 99.9%), Vertex Pharmaceuticals Incorporated would be worth roughly what it owes.
Total debt $1.98B against a stock market value of $132.06B.
Distance to default 17.12 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $988.8M (short-term plus half of long-term), stock volatility 28.8%; Altman Z'' 8.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.52 (down 99.9%), Vertex Pharmaceuticals Incorporated would be worth roughly what it owes.
Total debt $1.98B against a stock market value of $132.06B.
Distance to default 17.12 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $988.8M (short-term plus half of long-term), stock volatility 28.8%; Altman Z'' 8.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.40
Bullish
5 bullish
3 neutral
1 bearish
Articles (7d)
9
Daily Sentiment (7 Days)
Articles (100)
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
BHC Q3 Earnings Preview: Here's What You Should Know
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move
Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by Citizens Financial Group Inc. RI
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
Where Will CRISPR Therapeutics Stock Be in 2030?
Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
These healthcare stocks stand out with A+ growth grades
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
2 Healthcare Stocks That Just Delivered Great News for Investors
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by QRG Capital Management Inc.
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Envestnet Asset Management Inc.
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Vertex reports positive mid-stage results of inaxaplin for kidney disease
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?
Nykredit A S Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
Baird Financial Group Inc. Has $2.05 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
Engineers Gate Manager LP Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
My Top 5 Favorite Stocks for an Uncertain Market
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by NewEdge Advisors LLC
Vertex trades higher after JPM gives bullish rating
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
Why CRISPR Therapeutics Stock Rocked the Market Last Month
Where Will CRISPR Therapeutics Stock Be in 5 Years?
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
3 Stocks Whose Competitive Walls Tower Over Nvidia's
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Vertex wins Overweight at Morgan Stanley as coverage resumes after Crinetics buyout
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex, RWE, Adyen added to Goldman Sachs’ conviction lists for September
Vertex Pharmaceuticals names Jonathan Poole to CFO role
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
Ancora Advisors LLC Acquires Shares of 1,127 Vertex Pharmaceuticals Incorporated $VRTX
17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLC
White House is said to announce drug pricing deals with biotechs
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide
Notable healthcare headlines for the week: Moderna, Merck, and Twist Bioscience in focus
EP Wealth Advisors LLC Acquires New Position in Vertex Pharmaceuticals Incorporated $VRTX
Advisors Capital Management LLC Buys Shares of 1,258 Vertex Pharmaceuticals Incorporated $VRTX
Allworth Financial LP Invests $2.23 Million in Vertex Pharmaceuticals Incorporated $VRTX
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside?
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
B. Metzler seel. Sohn & Co. AG Acquires Shares of 231,381 Vertex Pharmaceuticals Incorporated $VRTX
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX
BOK Financial Private Wealth Inc. Makes New $471,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
Halvårsrapport 2026
Half-year report 2026
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook
Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say
Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates
Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more
Earnings Scoreboard: 84% of S&P 500 reporting firms top EPS estimates as 72% post Y/Y profit growth
3 things to look out for on Monday
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?